Inactivation of antiplasmin at low pH: Evidence for the formation of latent molecules

Thrombosis Research

Volumn 114, Issue 4, 2004, Pages 301-306

  Wang, Haiyao ^a   Pap, Sarolta ^a   Wiman, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiplasmin; Inactivation; Latent; Serpin; Stability

Indexed keywords

ANTIPLASMIN;

ARTICLE; INCUBATION TIME; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERIZATION; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE;

ANTIPLASMIN; DIMERIZATION; GUANIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; PROTEIN DENATURATION; PROTEIN RENATURATION; SERPINS; TEMPERATURE;

EID: 4744358097     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.014     Document Type: Article

References (37)

1. Carrell R.W., Huntington J.A., Mushunje A., Zhou A. The conformational basis of thrombosis. Thromb. Haemost. 86:2001;14-22
2. Shore J.D., Day D.E., Francis-Chmura A.M., Verhamme I., Kvassman J., Lawrence D.A., et al. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270:1995;5395-5398
3. Wilczynska M., Fa M., Karolin J., Ohlsson P.I., Johansson L.B.Å., Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat. Struct. Biol. 4:1997;354-357
4. Stratikos E., Getting P.G.W. Mapping the serpin-proteinase complex using single cysteine variants of alpha1-proteinase inhibitor Pittsburgh. J. Biol. Chem. 273:1998;15582-15589
5. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 407:2000;923-926
6. Beauchamp N.J., Pike R.N., Daly M., Butler L., Makris M., Dafforn T., et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood. 92:1998;2696-2706
7. Chang W.S.W., Lomas D.A. Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema. J. Biol. Chem. 273:1998;3695-3701
8. Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 355:1992;270-273
9. Hekman C.M., Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260:1985;11581-11587
10. Lomas D.A., Elliott P.R., Chang W.S.W., Wardell M.R., Carrell R.W. Preparation and characterization of latent alpha 1-antitrypsin. J. Biol. Chem. 270:1995;5282-5288
11. Lindahl T., Wiman B. Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium. Biochim. Biophys. Acta. 994:1989;253-257
12. Sancho E., Declerck P.J., Price N.C., Kelly S.M., Booth N.A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry. 34:1995;1064-1069
13. Berkenpas M.B., Lawrence D.A., Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14:1995;2969-2977
14. Mångs H., Sui G.C., Wiman B. PAI-1 stability: the role of histidine residues. FEBS Lett. 475:2000;192-196
15. Lindahl T.L., Sigurdardottir O., Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb. Haemost. 62:1989;748-751
16. Chmielewska J., Carlsson T., Urden G., Wiman B. On the relationship between different molecular forms of the fast inhibitor of tissue plasminogen activator. Fibrinolysis. 1:1987;67-73
17. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Paques E.P., Preissner K.T., et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263:1988;15454-15461
18. Wiman B., Almquist Å., Sigurdardottir O., Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett. 242:1988;125-128
19. Lindahl T.L., Sigurdardottir O., Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb. Haemost. 62:1989;748-751
20. Wardell M.R., Chang W.S., Bruce D., Skinner R., Lesk A.M., Carrell R.W. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry. 36:1997;13133-13142
21. Mast A.E., Enghild J.J., Salvesen G. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry. 31:1992;2720-2728
22. Huntington J.A., Pannu N.S., Hazes B., Read R., Lomas D.A., Carrell R.W. A 2.6 A structure of a serpin polymer and implications for conformational disease. J. Mol. Biol. 293:1999;449-455
23. Dunstone M.A., Dai W., Whisstock J.C., Rossjohn J., Pike R.N., Feil S.C., et al. Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 9:2000;417-420
24. Bruce D., Perry D.J., Borg J.Y., Carrell R.W., Wardell M.R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp). J. Clin. Invest. 94:1994;2265-2274
25. Lindo V.S., Kakkar V.V., Learmonth M., Melissari E., Zappacosta F., Panico M., et al. Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br. J. Haematol. 89:1995;589-601
26. Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 357:1992;605-607
27. Lomas D.A., Finch J.T., Seyama K., Nukiva T., Carrell R.W. Alpha 1-antitrypsin Siiyama (Ser53→Phe): further evidence for intracellular loop-sheet polymerisation. J. Biol. Chem. 268:1993;15333-15335
28. Mahadeva R., Chang W.S.W., Dafforn T., Oakley D.J., Foreman R.C., Calvin J., et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J. Clin. Invest. 103:1999;999-1006
29. Wilczynska M., Lobov S., Ohlsson P.I., Ny T. A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerisation. EMBO J. 22:2003;1753-1761
30. Wiman B., Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur. J. Biochem. 78:1977;19-26
31. Wiman B. Affinity-chromatographic purification of human alpha 2-antiplasmin. Biochem. J. 191:1980;229-232
32. Wiman B. Methods in enzymology: human α 2-antiplasmin. 1981;395-408 Academic Press, New York
33. Jovin T.M. Multiphasic zone electrophoresis: IV. Design and analysis of discontinuous buffer systems with a digital computer. Ann. N. Y. Acad. Sci. 209:1973;477-496
34. Stout T.J., Graham H., Buckley D.I., Matthews D.J. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry. 39:2000;8460-8469
35. Zhou A., Stein P.E., Huntington J.A., Carrell R.W. Serpin polymerization is prevented by a hydrogen bond network that is centered on his-334 and stabilized by glycerol. J. Biol. Chem. 278:2003;15116-15122
36. Carrell R.W., Stein P.E., Fermi G., Wardell M.R. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 2:1994;257-270
37. Dafforn T.R., Mahadeva R., Elliott P.R., Sivasothy P., Lomas D.A. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J. Biol. Chem. 274:1999;9548-9555